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Background Patients with Parkinson’s disease experience visual symptoms, partially originating 
from retinal changes. Since 2011, multiple case-control studies using spectral-domain OCT, 
which allows for studying individual retinal layers, have been published. The aim of this study 
was to substantiate the occurrence, extent, and location of retinal degeneration in Parkinson’s by 
meta-analysis. 
 
Methods Spectral-domain OCT case-control data were collected by performing a search in 
PubMed and Embase with terms: “optical coherence tomography” and “parkinson”, up to 
November 5th 2018. Studies with fewer than 10 patients or controls were excluded. We 
performed a random effects meta-analysis. Heterogeneity was evaluated with I2 statistics; 
publication bias with Egger’s and Begg´s tests. 
 
Results Out of 77 identified studies, 36 were included, totaling 1916 patients and 2006 controls. 
A significant thinning of the peripapillary retinal nerve fiber layer (d = -0.42; 95% confidence 
interval -0.54 to -0.29) and the combined ganglion cell and inner plexiform layers (d = -0.40; -
0.72, to -0.07) was found. The inner nuclear layer and outer plexiform layer did not show 
significant changes. Heterogeneity ranged from 3 to 92%; no publication bias was found. 
 
Conclusions Parkinson’s patients show significant thinning of the inner retinal layers, 
resembling changes found in glaucoma and other neurod generative diseases like Alzheimer's. 
Study of different cell layers in-vivo is possible by moving from time-to spectral domain OCT. 
Retinal degeneration may be affiliated with neurodegenerative pathology overall, and could 
serve as a biomarker in neurodegenerative disorders. Longitudinal research including clinical 




















Parkinson’s disease is a progressive neurodegenerative disorder. Besides the motor symptoms, 
Parkinson’s disease may present with a variety of non-motor symptoms, including cognitive 
deficits [1,2], depression, REM-sleep behavior disorder, dementia [3], and also visual complaints 
and visual hallucinations [4–8]. As an extension of the central nervous system [9,10], the retina 
has drawn interest as a window into pathological processes in the brain. Multiple OCT studies 
have investigated the retina and report retinal nerve fiber layer (RFNL) thinning and ganglion 
cell layer (GCL) abnormalities in Parkinson’s disea [11–47], Alzheimer's disease, and multiple 
sclerosis [48,49]. However, the effects are subtle, mostly based on cross-sectional cohorts, with 
varying methodologies, resulting in very heterogeneous outcomes. Several studies have 
compared RFNL and GCL abnormalities in Parkinson’s [35,43] and Alzheimer’s [48] with 
glaucoma. As reported in more detail in the Discussion ection, the thinning of the concerning 
retinal layers seems more pronounced in glaucoma than in Parkinson’s; the RNFL thinning 
topography, however, seems to mimic that of glaucoma, with a relative sparing of the fibres 
entering the optic nerve head nasally. 
 
Optical coherence tomography (OCT) [50], introduced in 1991, is a noninvasive technique that 
can be used for the in-vivo imaging of tissue. Light from a low-coherent light source is split into 
two bundles; one bundle is reflected by the tissue, th  other bundle by a reference mirror. Once 
reflected and brought together again, interference occurs. Tissue properties can be derived from 
the interference pattern and cell layers can be discriminated if their optical properties differ. In 
time-domain OCT (TD-OCT), the reference mirror is moved back and forth in order to get depth 
information from the tissue; in spectral-domain OCT (SD-OCT), different colors in the reflected 
light are analyzed in a sophisticated way, allowing for the retrievement of depth information 
without the need of a moving reference mirror. As a result, SD-OCT is faster and has a better 
signal-to-noise ratio [51,52]. With TD-OCT, only the (high-reflective) retinal nerve fiber layer 
(RNFL) and the retinal pigment epithelium (RPE) can be visualized (the distance between these 



















In 2014, an important meta-analysis on OCT in Parkinson’s disease was published [53]. This 
meta-analysis also reported results from TD-OCT. However, since then, many studies using SD-
OCT were published. Given the better signal-to-noise ratio of SD-OCT and the ability to assess 
all individual layers, we performed an updated meta-an lysis, incorporating these recent SD-
OCT studies, in order to see if more detailed results could be obtained of the retinal degeneration 
in Parkinson’s, and how these data compare to the current findings in other neurodegenerative 






A literature search was conducted in PubMed and Embase. The search term for PubMed was: 
“parkinson[All Fields] AND ("tomography, optical coherence"[MeSH Terms] OR 
("tomography"[All Fields] AND "optical"[All Fields] AND "coherence"[All Fields]) OR "optical 
coherence tomography"[All Fields] OR ("optical"[All Fields] AND "coherence"[All Fields] 
AND "tomography"[All Fields]))”. The search term for Embase was: “('parkinson disease'/exp 
OR 'parkinson disease') AND ('optical'/exp OR optical) AND ('coherence'/exp OR coherence) 
AND ('tomography'/exp OR tomography)”. The search and data extraction was performed by the 
first author (AC). The full text of potentially eligible studies was analyzed to check for in- and 
exclusion criteria. In addition, the reference listfrom all identified studies was checked. Authors 
were approached for missing, ambiguously presented, or unpublished data, and for corrections. 
PRISMA [54] guidelines were followed. Publications were included if published before 
November 5th 2018. 
 
Inclusion and exclusion criteria 
 
Studies were included if they (1) reported on retinal layer thicknesses assessed with SD-OCT, (2) 
had a case-control design, (3) included as least 10 Parkinson's patients and 10 controls, (4) 
reported the thickness of at least one retinal layer in the macular area or the peripapillary retinal 

















for the calculation of it from the data presented in the article. We excluded studies published in a 
non-English language and studies published before 2006, when the Federal Drug Administration 
approved SD-OCT [55]. We checked for duplicate analysis and, if present, we only included the 
most recent publication. The SD-OCT devices included in the meta-analysis were Cirrus HD-
OCT (Carl Zeiss Meditec, Dublin, California, USA), SOCT Copernicus (Optopol, Zawiercie, 
Poland), RT-Vue 100 (OptoVue, Fremont, California, USA), Spectralis (Heidelberg 




The number of Parkinson's patients, healthy subjects (controls), mean thickness values in µm and 
standard deviations were entered into the meta-essentials workbook function three comparing 
differences between independent groups and continuous data [56]. We calculated, per cell layer, 
the Cohen’s d effect size of each study and subsequently the corresponding pooled effect size 
and 95% CI, using a random effects model. The random effects model was chosen because we 
expected a significant heterogeneity (different SD-OCT devices, different disease stages, etc.). 
Heterogeneity was evaluated using the I2 statistic. I2 is the percentage of the total variation across 
the studies that is due to heterogeneity. Values up to 25%, 25-49%, 50-74%, and 75% and above 
are considered no, low, moderate, and high heterogeneity, respectively. We performed a 
sensitivity analysis to evaluate the contribution of each individual study to the heterogeneity by 
sequentially leaving out one study and reanalyzing the pooled estimate for the remaining studies. 
Publication bias was assessed with Egger’s regression asymmetry test and Begg’s adjusted rank 
correlation test. In addition to the mean layer thicknesses, we also analyzed the pRNFL for four 
(superior, temporal, inferior, nasal) individual sectors and the overall thickness of the macular 
area for nine different regions of interest (ROIs) a  defined by the Early Treatment of Diabetic 
Retinopathy Study (ETDRS grid) [57]. For the sector wise and ROI wise analysis, we only 




















Overall 36 studies were included according our criteria. (Fig. 1). Table 1 presents the 
characteristics of the included population. One study [21] was included twice in the meta-
analysis, having reported two independent samples. The studies included originate from 2009-
2018. The numeration assigned to the 36 included stu ies in the tables corresponds to reference 
numbers 12-47. 
 
Table 2 presents the data underlying the random effects meta-analyses. A significant thinning 
was found for the pRNFL and the ganglion cell layer-inner plexiform layer (GCL-IPL); none of 
the outer retinal layers showed any significant thinning. Figs. 2 and 3 show the forest plots for 
the pRNFL (Fig. 2) and the GCL-IPL (Fig. 3). The pooled Cohen's d values across all studies 
were: pRNFL (d= -0.42; 95% confidence interval -0.54 to -0.29), GCL-IPL (d= -0.40; -0.72 to -
0.07), inner nuclear layer (INL) (d= -0.01; -1.03 to 1.01) and outer plexiform layer (OPL) (d= 
0.11; -0.25 to 0.47). As can be seen in Table 2, two studies reported on the outer nuclear layer 
(ONL) [27,46], however they were not meta-analyzed due to reporting thicknesses on different 
ROIs. One study reported on the combined IRLs (RNFL, GCL, and IPL) and ORLs (INL to 
retinal pigment epithelium) [12], and one on the retinal pigment epithelium (RPE). 
 
Some studies provided data regarding clinical characte istics. The most widely available clinical 
data were age and disease duration. There was no sig ificant correlation between the pRNFL 
weighted mean difference (Parkinson’s versus control) and mean age (Kendall’s tau-b 0.14; 95% 
CI -0.13 to 0.41, P=0.26) or the pRNFL weighted mean difference (Parkinson’s versus control) 
and disease duration (0.23; 0.01 to 0.45, P=0.06) in the studies listed in Table 2a. After 
excluding the studies done at medication off state, th re was no significant correlation between 
the pRNFL weighted mean difference (Parkinson’s versus control) and UPDRS III (Kendall’s 
tau-b 0.29; 95% CI -0.50 to 1.09, P=0.36), UPDRS total (0.40; -0.40 to 1.20, P=0.48),  and 
Hoehn & Yahr (HY) (0.22; -0.24 to 0.70, P=0.29). The number of studies done at medication off 
state was too small to calculate meaningful correlations (Table 1). 
 
Regarding heterogeneity, the I2 was 64% for the pRNFL, 75% for GCL-IPL, 82% for INL, and 
38% for OPL. The sensitivity analyses did not show a single study casting a significant undue 

















statistical evaluation of the funnel plots (Egger rgression: pRNFL P=0.11, GCL-IPL P=0.98, 
INL P=0.42, OPL P=0.08; Begg and Mazumdar rank correlation test: pRNFL P=0.15, GCL-IPL 
P=0.93, INL P=0.32, OPL P=1.0). 
 
Table 3 shows the summarized meta-analysis results for the overall (all layers together) retinal 
thickness in the macular area, for various ROIs. Fig 4 gives the corresponding summary forest 
plot. The retina appeared to be clearly thinner in Parkinson's patients compared to controls; this 
was the least pronounced in the fovea. 
 
Finally, Table 4 presents the summarized meta-analysis results for the sector specific layer 
thicknesses of the pRNFL. Fig. 5 shows the corresponding summary forest plot. A clear thinning 
was present in all sectors, except for the nasal sector. 
 
Several papers reported measures of clinical functio ing (Table 1) like the Unified Parkinson's 
Disease Rating Scale (UPDRS), Mini–Mental State Examin tion (MMSE) and the Hoehn & 
Yahr stage. We summarized the clinical details in Table 1. These data were collected at different 
states of the Parkinson’s patients and thus showed substantial heterogeneity. Therefore we did 




This meta-analysis shows that Parkinson’s patients have significantly thinner retinas compared to 
age- and gender-matched controls. Especially the inn r retinal layers are affected, consisting of 
the RNFL and GCL-IPL. The RNFL around the optic nerve head is affected mainly inferiorly, 
superiorly, and temporally, with an apparent sparing of the nasal sector. 
 
Comparison with previous studies on OCT in Parkinson’s disease 
 
Our meta-analysis confirms previous data of Yu et al. [53]. The main result from their study was 
that the mean pRNFL was significantly thinner in 644 Parkinson’s eyes versus 604 control eyes 

















quadrant (-7.6 µm) and the smallest effect in the nasal quadrant (-3.1 µm). We showed a 
significantly reduced mean pRNFL (-4.2 µm), with a significant thinning in all four pRNFL 
sectors, with the largest effect in the inferior quadrant (-6.0 µm) and the smallest effect in the 
nasal quadrant (-1.7 µm; Table 4, Fig. 5). Five of the thirteen studies [58–62] Yu et al. meta-
analyzed used TD-OCT; these too reported significant pRNFL thinning (on average -5.5 µm), in 
all sectors (superior, inferior, nasal, temporal). We extended the previous work by adding 30 SD-
OCT studies and analyzing all retinal cell layers including the pRNFL, GCL-IPL, INL, OPL, 
ONL as well as the overall retinal thickness in the macular region, divided in nine ROIs, which 
gives a more detailed picture of the findings in Parkinson’s patients. 
 
Limitations and strengths of this meta-analysis 
 
Most papers did not report on the ethnicity of their participants. Therefore we were not able to 
stratify our results by ethnic background. Another limitation involves the lack of uniformity and 
availability of the reported data. Many studies used different names and divisions of the retinal 
cell layers, and different clinical screening instruments. A strength of our analysis is the 
inclusion of a range of countries and ethnic backgrounds, and the diversity of SD-OCT machines 
used. Because the sensitivity analysis did not indicate any obvious study or device-related bias, 
this reinforces the validity of the reported main effect on retinal thickness. All studies excluded 
participants with pre-existing retinal disorders as po sible confounders, especially glaucoma and 
ocular hypertension. This is a limitation as glaucoma and Parkinson’s may share a common 
pathophysiology [63–66]. Data regarding the most affected side of the included Parkinson’s 
patients, compared with SD-OCT scans of both eyes, unfortunately was not sufficient for a meta-
analysis. Finally, a drawback of this meta-analysis is the fact that almost all studies were cross-
sectional, so no causal relationships could be establi hed based on these data. Future SD-OCT 
trials therefore should focus on longitudinal data collection.  
 


















Retinal degeneration has been identified in multiple diseases and neurodegenerative disorders 
[10,48,49,67,68]. This brings-up the question if the changes found in Parkinson’s patients are 
disease-specific or not. 
 
First of all the most recent OCT case-control meta-an lysis in glaucoma patients [69], including 
both TD-OCT and SD-OCT studies, showed a similar pattern compared to our meta-analysis in 
Parkinson’s patients, with relative sparing of the nasal sector of the pRNFL. This might indicate 
a common underlying pathophysiology, with a more progressive variant indicating glaucoma and 
a milder variant related to Parkinson’s patients [38,44]. In Alzheimer’s disease, slightly different 
findings were reported, existing of, the most recent OCT case control meta-analysis [70], 
including both TD-OCT and SD-OCT studies, reported a significant thinning in all (superior, 
inferior, nasal and temporal) quadrants of the pRNFL. Significant effects were also found for the 
macular thickness; including the outer ring, the inner ring, and the fovea. The smallest effect size 
was reported in the fovea, which agrees with our findings. 
 
Another argument for a possible interplay between glaucoma and Parkinson's can be found in the 
incidence figures of glaucoma in Parkinson's and vice versa. A 10-year retrospective study 
conducted in 2017 [66], reported an increased incidence of Parkinson’s in patients with primary 
open angle glaucoma, reporting a hazard ratio of 1.28 (95% CI; 1.05 to 1.46) in comparison to 
healthy controls. Also an increased incidence of glaucomatous findings in Parkinson’s disease 
patients (23.7%) [63], and a higher incidence of glaucoma (16.3% vs 6.6% in healthy controls) 
was reported [71]. Finally some basic pathological mechanisms show similarities in glaucoma, 
Parkinson's and Alzheimer's. The first one is the presence of microglial activation, as a marker of 
neuroinflammation, which has been reported in glaucoma as well as Parkinson's and 
Alzheimer's. Another common factor between glaucoma and Parkinson's/Alzheimer's is the 
deposition of proteins in the retina, like beta-amyloid, alpha-synuclein and phosphorylated tau, 




















At this moment it is unclear what the OCT findings in Parkinson's patients do mean with respect 
to the progression and diagnosis of Parkinson's. The cross-sectional studies are not useful to 
draw conclusions with respect to causality or the risk on Parkinson’s. However, the current OCT 
data show some interesting similarities in retinal thinning between glaucoma and/or Alzheimer's. 
Therefore OCT could become an interesting diagnostic tool because of its ease of use. The 
existing cross-sectional studies are only useful to look at correlations between OCT and clinical 
markers. One study showed that foveal thickness was inversely correlated with UPDRS (total 
UPDRS and motor scores) [26]. Another study [38] presented multiple inverse correlations of 
macular thickness (inner superior, inner nasal, inner i ferior, inner temporal, outer nasal, outer 
inferior, and outer temporal region) with disease severity, expressed by the Hoehn and Yahr 
stage. Disease duration was especially correlated with the thickness of the nasal RNFL quadrant. 
These correlations between retinal thickness and severity were confirmed by several other 
studies [12,20,22,23,26,39]. 
 
Future directions of research 
 
To get a better insight in the relationship between r tinal changes in glaucoma and 
neurodegenerative diseases like and Alzheimer's, it i  crucial to set-up and analyze longitudinal 
cohorts on glaucoma and or Alzheimer's, using SD-OCT, with extensive monitoring of the 
clinical features of these diseases. Thereabove, it would be very important to analyze cohorts of 




In conclusion, based on the current SD-OCT data, Parkinson’s patients do show thinning of the 
inner retinal layers, which resembles the retinal ptterns in glaucoma patients and different 
neurodegenerative diseases, like Alzheimer's disease. The question remains if this retinal 
thinning seen with SD-OCT could play a role as a possible biomarker. To solve that question, in 
depth longitudinal analyses are needed, with detailed clinical descriptions of the separate 
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Figure 1. PRISMA chart showing the study selection and inclusion process [54]. 
Figure 2. Thickness of the peripapillary retinal nerve fiber layer in Parkinson’s patients versus 
controls. Cohen’s d effect sizes per study and from meta-analysis. 
Figure 3. Thickness of the retinal ganglion cell layer and inner plexiform layer in Parkinson’s 
patients versus controls. Cohen’s d effect sizes per tudy and from meta-analysis. 
Figure 4. Overall retinal thickness in the macular area of Parkinson’s patients versus healthy 
controls, depicted as Cohen’s d effect sizes from the meta-analyses summarizing the various 
regions of interest. 
Figure 5. Thickness of the peripapillary retinal nerve fiber layer in Parkinson’s patients versus 
























































1 Mohammedyusuf E. Hajee 2009 RTVue 24 17 64 (6.5) 63.5 (10.7) - - 2.9 - - - - - 
2 Elena Garcia-Martin 2012 Spectralis 75 75 64.4 64.2 66 65.6 7.5 - - - 28.9 (8.3) - 
3 Philipp Albrecht 2012 Spectralis 40 35 61.2 (2) - - - 8.1 36.4 (23.8) - 2.5 (0.2) - OFF 
4 M Satue 2013 Spectralis 100 100 64 64 - - 5.3 - - 2.73 - - 
5 Mohammad Rohani 2013 3D-OCT 27 25 54.5 (10.4) 55 (8) 74.1 68 5.6 - - - - - 
6 Serkan Kirbas 2013 Cirrus 42 40 59.3 (4.9) 57 (4.9) 47 62 - - - - - - 
7 Aysu Sen 2014 RTVue 35 11 62.4 (8) 61.18 (8) 43 45.5 3 - - - - - 
8 Elena Garcia-Martin 2014 Spectralis 129 129 68.7 69 55.8 55.8 8.4 - - 2.7 - - 
9 Elena Garcia-Martin 2014 Spectralis 46 33 70.7 69.6 63 64 7.7 - - 2.2 (0.8) - - 
10a Elena Garcia-Martin 2014 Spectralis 111 200 65.4 65.3 63.3 63 7.6 - - - - - 
10b Elena Garcia-Martin 2014 Spectralis 60 120 65.1 65.3 63.3 63 7.6 - - - - - 
11 Esin S. Sari 2014 Cirrus 54 54 66.6 (8.7) 66.6 (7.9) 55.6 51.9 5.1 - - 2.26 (0.9) - - 
12 Hasan Ali Bayhan 2014 RTVue 20 30 65.6 (7.1) 63.5 (5 ) 55 56.7 2.2 13.9 (5.6) 27.3 (11.9) 1.7(0.9) - - 
13 Jee-Young Lee 2014 Opko 56 30 69.6 (7.1) 64.8 (7.4) 39.3 46.7 - 26.4 (13.5) 52.2 (24.6) 2.2 (0.8) 24.1 (4.5) - 
14 Lucas Barasnevicius Quagliato 2014 RTVue 43 38 68.5 (7.6) 66.2 (8.9) 62.8 46.2 7 - 17.6 (8.9) 1.63 - OFF 
15 M Satue 2014 Spectralis 153 242 68 66 - - 5.3 - 25 2.5 - - 
16 Max Schneider 2014 Cirrus 65 41 66.2 (12) 65.1 (9.4) 60 53.7 8.9 29 (16.5) - - - OFF 
17 Nicolas M. Roth 2014 Cirrus 68 32 68.8 (8.1) 64.7 (7.5) 54.4 62.5 7.2 19 (10) - - - - 
18 Birthe Stemplewitz 2015 Cirrus 108 165 64.3 (12.3) 56.9 (13) 63.9 42.4 6.2 - - 2.1 (0.7) - - 
19 Diana Bittersohl 2015 Spectralis 109 82 64.3 (10.2) 56.9 (13) - - 6.2 - - - - - 
20 Manpreet Kaur 2015 Cirrus 20 20 58.6 (9.5) 58.4 (9.3) - - 5.8 19 (10.4) - 2 - - 
21 Pooja Mailankody 2015 Spectralis 30 30 53.4 (10.6) 53.5 (10.6) 73.3 73.3 5.3 - 30.5 (14.8) 1.73 (0.5) 29.3 (2.1) OFF 
22 Anastasia Pilat 2016 Copernicus 25 25 60.7 60.5 76 76 6 - - - - - 
23 Jagan A. Pillai 2016 Cirrus 20 34 62.6 (9.5) 65.1 (8.3) 55 41 - 23 (10.6) - - - OFF 
24 Muhsin Eraslan 2016 RTVue 25 23 58.6 (10.3) 56.6 (9) 64 65.3 5.7 - 34.4 (16.2) - - - 
25 Turgay Ucak 2016 Cirrus 30 30 68.5 (7.6) 66.2 (8.9) 63.3 53.3 4.9 15.2 (4.1) 42.2 (15.6) - 24.7 (4.5) - 
26 V Polo 2016 Cirrus 37 37 69 68 62.2 64.9 13.2 25 (8.2) - 2.7 (0.6) - - 
27 Maria Satue 2017 Spectralis 30 30 69.5 (6.6) 68.3 (8.5) 56.7 56.7 13.5 - - 2.7 (0.7) - - 














29 Duygu Gulmez Sevim 2018 Spectralis 41 35 59.6 (9.9) 59.4 (7.6) 51 54 4 - - - - - 
30 Femke Visser 2018 Spectralis 20 20 65 63 75 45 8 24 - 2 29 - 
31 Jiang Huang 2018 Cirrus 53 41 61.8 (9.9) 62.3 (9.7) 58 66 5.6 37.1 (16.6) - 1.9 (0.5) - - 
32 Juliane Matlach 2018 Cirrus 40 23 64.1 (8.3) 64.1 (8 2) 70 46 9.8 - - - - - 
33 Li-Jing Ma 2018 Cirrus 37 42 60.4 (8.4) 57.3 (9.5) 57 54 2.9 21.4 (11.5) 33.8 (15.2) 1.5 - OFF 
34 Marilita M. Moschos 2018 Spectralis 31 25 67.8 (3.9) 68 (4.1) 53.1 56 - - - - - - 
35 Metin Unlu 2018 Spectralis 58 30 59.7 (9.6) 60.2 (13.4) 53.5 50 8.4 (2.7) - - - - - 
36 Turkoglu Sule Aydin 2018 Spectralis 25 29 70 68 68 65.5 4 - 24 1 28 - 
 1916 2006 
 
 














Study PD patients (mean [SD]) Controls (mean [SD]) Difference Cohen's d (CI 95%) Weight 
Table 2a 
pRNFL (µm)  
2 97.2 (5.2) 101.5 (5.2) -4.4 -0.84 (-1.18, -0.51) 3.6% 
3 97.3 (10.2) 99.1 (9.4) -1.8 -0.18 (-0.64, 0.27) 2.9% 
4 98.7 (12) 101.9 (8.7) -3.2 -0.30 (-0.58, -0.03) 3.9% 
5 91.2 (10.5) 102.6 (13.5) -11.4 -0.93 (-1.53, -0.37) 2.3% 
6 77 (11.6) 89 (8.7) -12 -1.16 (-1.64, -0.70) 2.8% 
7 105.7 (9.5) 115.6 (9.1) -9.9 -1.04 (-1.77, -0.34) 1.8% 
8 98.4 (10.2) 100.8 (9.1) -2.4 -0.24 (-0.49, 0) 4.1% 
9 97.8 (8.4) 99.4 (10.1) -1.6 -0.17 (-0.62, 0.28) 2.9% 
10a 97.5 (14.5) 101.2 (9.1) -3.6 -0.32 (-0.55, -0.09) 4.2% 
10b 94.2 (17.1) 101.4 (8.4) -7.2 -0.60 (-0.92, -0.28) 3.7% 
11 89.7 (12) 93 (9.3) -3.3 -0.30 (-0.69, 0.07) 3.3% 
12 104.4 (13.3) 110.6 (12.2) -6.2 -0.48 (-1.07, 0.09) 2.3% 
14 103.1 (12) 105.9 (12.8) -2.8 -0.22 (-0.66, 0.22) 3.0% 
15 97.6 (11) 103.2 (11.3) -5.7 -0.50 (-0.71, -0.30) 4.4% 
17 92.6 (8.8) 91.5 (10.7) 1.1 0.12 (-0.31, 0.54) 3.1% 
18 91.2 (6.2) 91.6 (7.7) -0.4 -0.06 (-0.30, 0.19) 4.2% 
19 95.7 (9.4) 96.1 (7.2) -0.4 -0.05 (-0.33, 0.24) 3.9% 
20 85.4 (12.4) 91.1 (8) -5.7 -0.54 (-1.19, 0.09) 2.1% 
21 97.9 (11.9) 99.1 (10.7) -1.2 -0.10 (-0.62, 0.40) 2.6% 
22 96.9 (11.9) 109.3 (18.1) -12.4 -0.8 (-1.39, -0.23) 2.3% 
23 88.5 (9.4) 85.3 (9.3) 3.2 0.34 (-0.22, 0.90) 2.4% 
24 105.4 (13.5) 113.8 (8.5) -8.3 -0.72 (-1.32, -0.14) 2.3% 
25 89.4 (7.5) 94.6 (8.1) -5.3 -0.66 (-1.2, -0.15) 2.6% 
26 94.9 (11.5) 96.2 (6.7) -1.3 -0.14 (-0.6, 0.32) 2.9% 
27 96.4 (9.5) 98.2 (9.1) -1.8 -0.19 (-0.7, 0.32) 2.6% 
28 98 (8) 97.9 (11.7) 0.1 0.01 (-0.50, 0.51) 2.7% 
29 89.5 (8.7) 98.7 (11.3) -9.2 -0.91 (-1.40, -0.44) 2.8% 
30 91 (10) 92 (18) -1 -0.07 (-0.70, 0.56) 2.1% 
31 88.9 (18.8) 92.7 (11.5) -3.8 -0.23 (-0.65, 0.17) 3.1% 
32 88.5 (12.3) 93.6 (8.8) -5.1 -0.45 (-0.98, 0.07) 2.6% 
33 94.7 (7.3) 102.7 (5.1) -8 -1.27 (-1.77, -0.80) 2.7% 
34 95.1 (11.9) 103.9 (3.9) -8.8 -0.94 (-1.51, -0.39) 2.4% 
35 97.5 (8.6) 100 (10) -2.5 -0.27 (-0.72, 0.17) 3.0% 
36 97.1 (12.8) 104 (7.1) -6.9 -0.67 (-1.24, -0.13) 2.4% 





3 99.8 (8.1) 98.7 (9.5) 1.1 0.12 (-0.33, 0.58) 9.4% 
11 68.6 (16.3) 81.3 (6.3) -12.7 -1.02 (-1.43, -0.62) 9.9% 
13 70.2 (17.6) 79.8 (15.8) -9.6 -0.56 (-1.02, -0.11) 9.4% 
16 71.7 (8) 72.4 (6.7) -0.7 -0.09 (-0.49, 0.3) 10% 
17 78.1 (8) 79.2 (7.4) -1.1 -0.14 (-0.56, 0.28) 9.7% 
20 71.5 (15.8) 81.5 (5.3) -10 -0.83 (-1.50, -0.19) 7.6% 
22 82.7 (8.9) 83.7 (7.1) -1 -0.12 (-0.68, 0.44) 8.4% 
23 77.5 (14.2) 73.5 (11.3) 4 0.32 (-0.24, 0.88) 8.4% 













26 82.7 (6.2) 84.8 (4.1) -2.1 -0.39 (-0.86, 0.06) 9.3% 
35 78.6 (3.4) 82.6 (2.5) -4 -1.26 (-1.75, -0.79) 9.1% 
Overall Effect 78.1 81.7 -3.6 -0.40 (-0.72, -0.07)  
Table 2c 
INL (µm)  
3 46.8 (5.9) 42.8 (4.1) 4 0.77 (0.31, 1.26) 19.9% 
13 30.7 (6.3) 35.2 (7.5) -4.4 -0.65 (-1.11, -0.20) 20.1% 
16 36 (3.2) 37.2 (2.9) -1.2 -0.39 (-0.78, 0.01) 21% 
22 36.8 (5.6) 35.4 (5.8) 1.4 0.24 (-0.32, 0.80) 18.6% 
35 36.6 (2.9) 36.9 (3.9) -0.3 -0.03 (-0.72, 0.66) 20.3% 
Overall Effect 37.4 37.5 -0.1 -0.01 (-1.03, 1.01)  
Table 2d 
OPL (µm)  
3 33.7 (4.6) 34.6 (6.1) -0.9 -0.16 (-0.62, 0.30) 20% 
13 32.1 (7.9) 29.7 (5.1) 2.5 0.34 (-0.10, 0.80) 20.4% 
16 24.5 (5.1) 25 (3.5) -0.5 -0.11 (-0.50, 0.28) 23.7% 
22 28.6 (5.5) 28.6 (5.5) 0 0 (-0.56, 0.56) 15.5% 
35 30.7 (3) 29.3 (2.7) 1.4 0.48 (0.03, 0.93) 20.4% 
Overall Effect 30 29.4 0.5 0.11 (-0.25, 0.47)  
Table 2e 
ONL (µm)  
16 121.2 (9.6) 124.1 (10.2) -2.9 
35 59.6 (8.3) 68.8 (15.4) -9.2 
ORL (µm)  
1 169.1 (7.7) 169.2 (23.3) -0.1 
IRL (µm)  
1 89.3 (11.2) 103.7 (23.9) -14.4 
RPE (µm)  
35 13.7 (1.3) 15.1 (2.1) -1.4 
pRNFL = peripapillary retinal nerve fiber layer; GCL-IPL = ganglion cell complex-inner plexiform layer; INL = 
inner nuclear layer; OPL = outer plexiform layer; ONL = outer nuclear layer; ORLs = outer retinal layer; IRLs = 















Macula (µm) Weighted Mean Weighted average N I^2 
 PD (SD) Control (SD) Difference Cohen's d (CI 95%) PD Control  
Fovea 271.2 (24.2) 274.3 (20.3) -2.8 -0.12 (0.02, -.26) 702 874 18.4% 
Inferior inner 324.2 (20.5) 331.6 (17) -7.7 -0.43 (-0.10, -0.76) 702 874 85.9% 
Inferior outer 277.3 (19.5) 286.6 (16.8) -9.4 -0.50 (-0.07, -0.93) 702 874 92% 
Nasal inner 329 (19.8) 335.3 (18.1) -6.8 -0.37 (-0.14, -0.59) 702 874 72.1% 
Nasal outer 299.9 (20.4) 307.5 (17.7) -8 -0.43 (-0.19, -0.66) 702 874 75% 
Superior inner 327.8 (20.4) 334.7 (17) -7.4 -0.43 (-0.14, -0.72) 702 874 80.8% 
Superior outer 286.8 (17.6) 296.1 (15.8) -9.5 -0.57 (-0.17, -0.98) 702 874 91.3% 
Temporal inner 316.1 (20.2) 323.4 (16.8) -7.7 -0.45 (-0.21, -0.69) 702 874 73.8% 
Temporal outer 272.4 (19.3) 278.6 (17.1) -6.6 -0.39 (-0.17, -0.61) 702 874 70.1% 















pRNFL sectors (µm) Weighted Mean Weighted average N I^2 
 PD (SD) Control (SD) Difference Cohen's d (CI 95%) PD Control  
Inferior 120.3 (19.8) 125.6 (17.3) -6 -0.33 (-0.20, -0.45) 651 716 59.7% 
Nasal 71.7 (14.3) 73.2 (12.9) -1.7 -0.14 (0.05, -0.32) 651 716 53% 
Superior 116.2 (16.9) 119.8 (15.1) -4.2 -0.26 (-0.12, -0.40) 651 716 51.4% 
Temporal 66.7 (13) 70.6 (11.6) -3.7 -0.30 (-0.19, -0.40) 651 716 0% 










































































● Retinal cell layers are thinner in Parkinson’s compared to healthy controls, 
overall. 
● The retinal nerve fiber layer, ganglion cells and iner plexiform layer are 
thinner. 
● The inner nuclear layer and outer plexiform layer showed no difference. 
● The peripapillary nasal sector appears to be less affected compared to other 
sectors. 
● The macula is thinner, however the fovea appears to be less affected. 
